As Emergent Partnership Dissolves, BARDA Looks To Revamp Post-COVID Pandemic Preparedness
BARDA terminates CIADM contract in wake of vaccine cross-contamination incident, begins discussion with industry about next steps for rapid pandemic response capabilities.
You may also be interested in...
For Next Pandemic, BARDA Proposes New Consortia For Rapid Response
HHS agency would expand on DOD consortium approach that delivered the COVID-19 vaccines to bring together private sector teams that could quickly defend the US against future infectious outbreaks. Plan also calls for working with commercial lenders for the capital required to expand production of medical countermeasures.
FDA Warning Letter Brings Another High-Flying Emergent CDMO Plant Down To Earth
Warning letter reveals agency found quality problems at Emergent BioSolutions’ Camden fill/finish plant during COVID-19 pandemic even as firm’s Bayview plant came under heightened scrutiny. Metal particulates appeared in vials as Camden plant and rest of Emergent’s CDMO network experienced sharp demand growth.
Novavax’s Vaccine Switched Manufacturing Facilities Multiple Times Prior To EUA
One switch raised questions, but by the time the COVID-19 vaccine reached commercial scale, the changes were considered minor.